| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 26 | 47.7x | 17.8x | Bottom tier | |
Growth | 99 | — | 7.1% | Top tier | |
Quality | 96 | 58.4% | 4.5% | Top tier | |
Safety | 78 | — | 2.6x | Top tier | |
Capital Return | 79 | — | 2.12% | Top tier | |
Momentum | 90 | 221.4% | 2.9% | Top tier | |
Sentiment | 34 | 5 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Liquidia Corporation is a commercial biotechnology company focused on therapies for pulmonary hypertension, and its current revenue model comes almost entirely from sales of YUTREPIA, a dry-powder inhaled treprostinil product. According to management's presentation on August 12, 2026, the product's appeal is based on ease of dose titration, tolerability, and the ability to reach higher doses, while the company is expanding the franchise through twice-daily L606 and additional studies covering PAH, PH-ILD, Raynaud syndrome, and pulmonary fibrosis.
In the second quarter of fiscal 2026, revenue reached $171.7 million, including $170.4 million in YUTREPIA net sales, representing about 99% of revenue, and product sales rose 31% from the previous quarter by more than $40 million. Net income was $74.7 million, or $0.74 per share, compared with revenue of $132.9 million and net income of $52.9 million in the first quarter of fiscal 2026; the reported overall net margin was 30.7%, and the gross margin for the main product was 93.7%.
For the trailing twelve months ended in 2026, Liquidia recorded revenue of $450.9 million, net income of $138.6 million, and earnings per share of approximately $1.37, marking a sharp turnaround from fiscal 2025, when it recorded revenue of $158.3 million, a net loss of $68.9 million, and negative earnings per share of $0.80. The company ended the second quarter of fiscal 2026 with cash and cash equivalents of $284.2 million, up $61.4 million from the previous quarter and approximately $93.5 million since the beginning of fiscal 2026.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $98.11, which is above the 52-week range high of $93.61, with a consensus rating of “Buy.” However, the extreme disparity between the lowest target of $36 and the highest target of $130, compared with a 52-week range of $21.15 to $93.61, highlights the valuation's sensitivity to the sustainability of YUTREPIA's growth, the outcome of the legal case, and the success of the study pipeline; no published price-to-earnings ratio is available to provide an additional valuation anchor.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
The primary driver is YUTREPIA, which recorded net sales of $170.4 million in the second quarter of fiscal 2026. The product represented about 99% of the company's total revenue of $171.7 million in that quarter. As of July 31, 2026, more than 5,000 patients had started treatment, and more than 1,100 physicians had prescribed the product.
YUTREPIA net sales increased 31% from the previous quarter, or by more than $40 million, to reach $170.4 million. Management said on August 12, 2026 that its quarterly sales had more than tripled over three quarters. The product also approached 30% of the inhaled treprostinil market based on net revenue.
Liquidia recorded net income of $74.7 million and earnings per share of $0.74 in the second quarter of fiscal 2026. Net income was $52.9 million in the first quarter of fiscal 2026, while the company said the second quarter was its fourth consecutive quarter of increasing profitability. For the trailing twelve months ended in 2026, net income reached $138.6 million, compared with a loss of $68.9 million in fiscal 2025.
Management said during the August 12, 2026 call that it expects to exceed $1 billion in net revenue in 2027. This confidence is based on the linear trajectory of referrals and treatment starts and on the sales team expansion that entered the field in June 2026. However, management did not commit to an acceleration in the rate of patient additions resulting from broader community outreach, emphasizing only its confidence in the continuation of the existing trajectory.
L606 is an inhaled treprostinil product in development with twice-daily dosing, compared with four doses daily for YUTREPIA. A 48-week open-label study showed that patients could titrate across multiple doses with a low adverse-event burden and continued improvement in walk distance throughout the dosing interval. As of August 12, 2026, the Phase 3 Re-Spire study was enrolling patients and progressing according to the announced schedule, but proof of the ultimate clinical advantage remains dependent on the results of this study.
The legal case related to the 327 trial could result in a royalty or another judicial remedy if the ruling goes against Liquidia, and as of August 12, 2026, management did not know when the decision would be issued. Operationally, approximately 99% of second-quarter fiscal 2026 revenue comes from YUTREPIA, creating high concentration in a single product. The company also expects to double research and development expenses in the second half of fiscal 2026 compared with the first half, then increase them again in 2027.
